Supplementary Material for A global atlas of genetic associations of 220 deep phenotypes.


Sakaue and Kanai et al.

Table of Contents:

- Page 3 Extended Data Figure 1
- Page 4 Extended Data Figure 2
- Page 5 Extended Data Figure 3
- Page 6Extended Data Figure 4Page 7Extended Data Figure 5
- Page 8 Extended Data Figure 6
- Page 9 Extended Data Figure 7
- Page 10 Extended Data Figure 8
- Page 11 Extended Data Figure 9
- Page 12 Extended Data Figure 10
- Page 13 Extended Data Figure 11
- Page 14 Extended Data Figure 12
- Page 15 Extended Data Figure 13
- Page 16 Extended Data Figure 14
- Page 17 Extended Data Figure 15
- Page 18 Extended Data Figure 16
- Page 19 Extended Data Figure 17
- Page 20 Supplementary Notes
- Page 30 Supplementary References

Supplementary Tables are provided by a separate excel file.


Extended Data Figure 1.



Extended Data Figure 1 | Overview of this study.

We performed 220 deep-phenotype GWASs in BioBank Japan, including 108 novel GWASs ever conducted in East Asian population. We performed trans-biobank meta-analyses with UK Biobank and FinnGen ($n_{total} = 628,000$), resulting in discovery of 4,168 novel loci. All summary statistics will be openly shared through web database. As downstream analyses, we performed (i) cross-population comparison of pleiotropy and genetic correlation, (ii) comprehensive HLA fine-mapping, and (iii) statistical decomposition of a matrix of summary statistics to gain insights into biology underlying current disease classifications, by incorporating functional genomics, metabolomics, and biomarker data.






Extended Data Figure 2 | Locus plot for Pulmonary Tuberculosis (PTB) in BBJ.

Regional association plots are shown. The lead variant (rs140780894) is colored in pink, and colors of other dots indicate linkage disequilibrium measure r^2 with the lead variant.


Extended Data Figure 3.



Extended Data Figure 3 | Locus plot for cholelithiasis in BBJ.

Regional association plots are shown. The lead variant (rs715) is colored in pink, and colors of other dots indicate linkage disequilibrium measure r^2 with the lead variant.


Extended Data Figure 4.



Extended Data Figure 4 | Locus plot for gastric diseases in BBJ.

Regional association plots at the *PSCA* locus in gastric ulcer, gastric cancer, and gastric polyp are shown. Rs2976397, which was a lead variant in gastric ulcer, is colored in pink, and colors of other dots indicate linkage disequilibrium measure r^2 with the lead variant.






Extended Data Figure 5 | Locus plot for gall bladder diseases in BBJ.

Regional association plots at the *FUT3* locus in gall bladder polyp and cholelithiasis are shown. Rs28362459, which was a lead variant in gall bladder polyp, is colored in pink, and colors of other dots indicate linkage disequilibrium measure r^2 with the lead variant.


Extended Data Figure 6.



Extended Data Figure 6 | Locus plot for urticaria in BBJ.


Regional association plots are shown. The lead variant (rs56043070) is colored in pink, and colors of other dots indicate linkage disequilibrium measure r^2 with the lead variant.

Extended Data Figure 7.



Extended Data Figure 7 | Locus plot for salicylic acids prescription in BBJ.


Regional association plots are shown. The lead variant (rs151193009) is colored in pink, and colors of other dots indicate linkage disequilibrium measure r^2 with the lead variant.



Extended Data Figure 8 | The effect size correlation between BBJ GWAS and European GWAS.

The marginal effect sizes of genome-wide significant variants across traits (diseases and biomarkers) in BBJ are compared with those in European GWAS. Each plot represents a variant, and is colored based on the significance in European GWAS as shown in the left top legend. Pearson's correlation *r* and *P* value between BBJ GWAS and European GWAS are also shown in the legend.


Extended Data Figure 9.



Extended Data Figure 9 | Phenotypic correlation across 220 phenotypes in BBJ

a. Heatmap of pair-wise phenotypic correlation matrix. The color of the cells indicates the value of correlation *r* as shown in a color scale at the bottom. The traits (rows and columns) were hierarchically clustered by hclust library in R. **b**. Silhouette score for clustering of closely related phenotypes with different number of clusters (**Supplementary Notes**).

Extended Data Figure 10.




Extended Data Figure 10 | The degree of pleiotropy in BBJ after accounting for phenotypic or genetic correlations

The Manhattan-like plots show the number of significant associations ($P < 5.0 \times 10^{-8}$) at each tested genetic variant in Japanese. **a**. For all traits ($n_{\text{trait}} = 220$; as shown in Figure 2a). **b**. After accounting for phenotypic correlations. **c**. After accounting for genetic correlations.


Extended Data Figure 11.

a Japanese



- cardiovascular- acting medications
- coronary artery disease
- type 2 diabetes- related phenotypes
- allergy- related phenotypes
- blood-cell phenotypes
 others

b Europeans




Extended Data Figure 11 | Genetic correlation matrices across populations.

The matrices describe pairwise genetic correlation r_{gs} in Japanese GWAS (**a**; n = 5,565) and in European GWAS (**b**; n = 10,878), which were estimated by bivariate LD score regression. A color of the cells indicates the value of r_{g} as shown in a color scale at the bottom. The traits (rows and columns) were hierarchically clustered by hclust library in R, and trait domains are displayed as colored boxes (see **Methods**).

r_g


Extended Data Figure 12.



Extended Data Figure 12 | A scree plot from the decomposition of summary statistics.

A scree plot summarizes cumulative explained variance by the 40 components from TSVD. We calculated variance explained by each component from the ".explained_variance_ratio_" from TruncatedSVD module in python package.


Extended Data Figure 13.



Extended Data Figure 13 | Network representation of the TSVD analysis.


Two-dimensional illustration of interconnection among 159 diseases and 40 latent components. Plots in blue indicate each trait's statistics, and plots in pink indicate the latent components derived by TSVD. White lines represent the contribution of each phenotype in each component. The width of the lines indicates the strength of the contribution based on the squared cosine score.

Extended Data Figure 14.



Extended Data Figure 14 | Enrichment analyses of genes explaining each component with tissue specificity.


A heatmap representation of the enrichment analyses of genes explaining each component with tissuespecific genes defined by GTEx expression profile (**a**) and regulatory vocabulary from ENCODE3 data (**b**). Each cell is colored based on $P_{\text{enrichment}}$ from Fisher's exact tests to assess the enrichment of the genes comprising each component within each tissue-specific gene set as shown in a color scale at the bottom right. **Extended Data Figure 15.**



Extended Data Figure 15 | Heatmap representation of squared cosine scores of diseases to components.

The components (rows) are shown from 1 (top) to 40 (bottom), and the diseases (columns) are sorted based on the contribution of each component to the disease based on the squared cosine score (from component 1 to 40). Each cell is colored based on the squared cosine score of a given trait to a given component, as shown in a color scale at the bottom right.


Extended Data Figure 16.



Extended Data Figure 16 | Drug target enrichment analysis.

The enrichment *P* value from Fisher's exact test of disease-associated genes against target genes of approved drugs for the disease is illustrated as a heatmap. The color of each cell indicates the $-\log_{10}(P)$ value of the enrichment of associated genes with each disease category to target genes of approved medication to a given disease category as shown in the color scale (top right). The disease category is ordered as an alphabetical code of the ICD10 classifications. The enrichment with nominal significance (*P* < 0.05) is highlighted as a box with a red border.

Extended Data Figure 17.



Extended Data Figure 17 | Genetic variants analyzed in the three cohorts.

The Venn diagram showing the number of genetic variants analyzed in this study in each of the three cohorts (BBJ, UKB, and FinnGen) and overlapping variants across the cohorts.

Supplementary Notes

1. Cohort descriptions

The Biobank Japan

The BioBank Japan (BBJ) Project is a nation-wide hospital-based prospective cohort launched in 2003. The BBJ collaboratively collected serum as well as clinical data of approximately 200,000 participants from 66 hospitals affiliated with 12 medical institutes. Participants were registered to the cohort from June 2003 to March 2008, and their clinical information was collected annually via interviews and medical record reviews until 2013. We collected DNA from all participants at baseline and collected annual serum samples until 2013.

The UK Biobank

The UK Biobank project is a population-based prospective cohort that recruited approximately 500,000 people aged between 40–69 years from 2006 to 2010 from across the United Kingdom. Deep phenotype data, such as electronic medical records, lifestyle indicators and bioassays (e.g., biochemistry, proteomic and metabonomic analyses), and genotype data were available for most of the participants. The detailed characteristics of the cohort were extensively described elsewhere¹.

FinnGen

FinnGen is a public–private partnership project. Six regional and three country-wide Finnish biobanks participate in FinnGen. Additionally, data from previously established population and disease-based cohorts are utilized. Participants' health outcomes are followed up by linking to the national health registries (1969–2016), which collect information from birth to death. A list of FinnGen contributors is presented below.

The Tohoku Medical Megabank (TMM)

The Tohoku Medical Megabank (TMM) Project was launched for the purpose of reconstruction from the Great East Japan Earthquake on 11 March 2011 and establishment of personalized healthcare and medicine². In the project, an integrated biobank has been established based on two prospective genome cohort studies ("the TMM Community-Based Cohort Study" and "Birth and Three-Generation Cohort Study"). Although the cohort studies recruited residents in Miyagi or Iwate Prefecture, only the participants living in Miyagi Prefecture, whose measurements on metabolites were available, were used in the study.

2. Evaluation of regional pleiotropy after accounting for phenotypic and genetic correlations

When traits are phenotypically or genetically dependent, the number of closely related traits might affect the level of pleiotropy by overestimating pleiotropy at the loci harboring genetic associations with a large number of closely related traits. To evaluate the potential effect of phenotypically or genetically correlated traits on the quantified degree of pleiotropy, we sought to assess the degree of pleiotropy after accounting for phenotypic and genetic correlations. First, to account for the phenotypic correlations, we defined phenotypically correlated trait domains as in Watanabe et al³. Briefly, we extracted 220 BBJ trait values per individual and computed the phenotypic correlation (r_p) as the Pearson's correlation (**Extended Data Figure 9a**). We replaced non-significant correlation (r_p) between pairs of traits after Bonferroni correction of multiple testing (P > 0.05/220) with zero. We next clustered traits based on the phenotypic correlations using hierarchical clustering ("hclust" in R) by optimizing the number of clusters k while maximizing silhouette score. In our case, at k = 139 the silhouette score was maximized (**Extended Data Figure 9b**) and we defined closely-related trait domains using this clustering result. Finally, we re-quantified the degree of pleiotropy by aggregating and counting the number of genome-wide significant associations across these trait domains (i.e., the association within a trait domain with multiple traits will be counted only once; **Extended Data Figure 10b**). For the definition of genetically closely related traits, we adopted the trait domains based on the genetic correlation matrix of r_g for consistency (see **Methods**). Then, we re-quantified the degree of pleiotropy by aggregating and counting the number of genome-wide significant association the trait domains based on the genetic correlation matrix of r_g for consistency (see **Methods**). Then, we

3. Statistical fine-mapping of the top pleiotropic loci in Biobank Japan (ALDH2 and GCKR)

We retrieved statistical fine-mapping results of the top pleiotropic loci (*ALDH2* and *GCKR*) from 67 overlapping traits studied in our ongoing study (Kanai et al., unpublished data). We used the same fine-mapping pipeline as previously described (Atkinson et al.⁴ and <u>https://www.finucanelab.org/data</u>). Briefly, we used FINEMAP version 1.3.1⁵ and susieR version 0.8.1.0521⁶ for fine-mapping. As input, we used the GWAS summary statistics and in-sample dosage linkage disequilibrium (LD) matrices computed by LDstore version 2.0b. We defined regions based on 3 Mb window around lead variants and merged them if they overlapped. The maximum number of causal variants in a region was specified as ten.

We found that out of 36 and 18 traits in which rs671 (*ALDH2*) and rs1260326 (*GCKR*) are genomewide significant ($P < 5.0 \times 10^{-8}$), 36 and 16 traits have the variant in 95% credible set, respectively. For the remaining two *GCKR* traits, we confirmed there are no additional independent signals in the locus. Altogether, these results suggest that our current approach is sufficient for the top two pleiotropic loci we identified. Further fine-mapping study should be warranted to elucidate a global landscape of pleiotropic variants in the future.

4. Contributors of FinnGen

Steering CommitteeAarno PalotieInstitute for Molecular Medicine Finland, HiLIFE, University of Helsinki, FinlandMark DalyInstitute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Pharmaceutical companies

Howard Jacob	Abbvie, Chicago, IL, United States
Athena Matakidou	Astra Zeneca, Cambridge, United Kingdom
Heiko Runz	Biogen, Cambridge, MA, United States
Sally John	Biogen, Cambridge, MA, United States
Robert Plenge	Celgene, Summit, NJ, United States
Mark McCarthy	Genentech, San Francisco, CA, United States

Julie Hunkapiller	Genentech, San Francisco, CA, United States
Meg Ehm	GlaxoSmithKline, Brentford, United Kingdom
Dawn Waterworth	GlaxoSmithKline, Brentford, United Kingdom
Caroline Fox	Merck, Kenilworth, NJ, United States
Anders Malarstig	Pfizer, New York, NY, United States
Kathy Klinger	Sanofi, Paris, France
Kathy Call	Sanofi, Paris, France

University of Helsinki & Biobanks

Tomi Mäkelä	HiLIFE, University of Helsinki, Finland, Finland
Jaakko Kaprio	Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland, Finland
Petri Virolainen	Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland
Kari Pulkki	Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland
Terhi Kilpi	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Markus Perola	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Jukka Partanen	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland
Anne Pitkäranta	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Riitta Kaarteenaho	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland
Seppo Vainio	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland
Kimmo Savinainen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland
Veli-Matti Kosma	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland
Urho Kujala	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland

Other Experts/ Non-Voting Members

Outi Tuovila	Business Finland, Helsinki, Finland
Minna Hendolin	Business Finland, Helsinki, Finland
Raimo Pakkanen	Business Finland, Helsinki, Finland

Scientific Committee

Pharmaceutical companies

Jeff Waring	Abbvie, Chicago, IL, United States
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States
Athena Matakidou	Astra Zeneca, Cambridge, United Kingdom
Heiko Runz	Biogen, Cambridge, MA, United States
Jimmy Liu	Biogen, Cambridge, MA, United States
Shameek Biswas	Celgene, Summit, NJ, United States
Julie Hunkapiller	Genentech, San Francisco, CA, United States
Dawn Waterworth	GlaxoSmithKline, Brentford, United Kingdom
Meg Ehm	GlaxoSmithKline, Brentford, United Kingdom
Dorothee Diogo	Merck, Kenilworth, NJ, United States
Caroline Fox	Merck, Kenilworth, NJ, United States
Anders Malarstig	Pfizer, New York, NY, United States
Catherine Marshall	Pfizer, New York, NY, United States
Xinli Hu	Pfizer, New York, NY, United States
Kathy Call	Sanofi, Paris, France
Kathy Klinger	Sanofi, Paris, France
Matthias Gossel	Sanofi, Paris, France

University of Helsinki & Biobanks

Samuli Ripatti

Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland Johanna Schleutker Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland

Markus Perola	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Mikko Arvas	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland
Olli Carpen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Reetta Hinttala	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland
Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland
Reijo Laaksonen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland
Arto Mannermaa	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland
Juha Paloneva	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland
Urho Kujala	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland

Other Experts/ Non-Voting Members

Outi Tuovila	Business Finland, Helsinki, Finland
Minna Hendolin	Business Finland, Helsinki, Finland
Raimo Pakkanen	Business Finland, Helsinki, Finland

Clinical Groups

Neurology Group	
Hilkka Soininen	Northern Savo Hospital District, Kuopio, Finland
Valtteri Julkunen	Northern Savo Hospital District, Kuopio, Finland
Anne Remes	Northern Ostrobothnia Hospital District, Oulu, Finland
Reetta Kälviäinen	Northern Savo Hospital District, Kuopio, Finland
Mikko Hiltunen	Northern Savo Hospital District, Kuopio, Finland
Jukka Peltola	Pirkanmaa Hospital District, Tampere, Finland
Pentti Tienari	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Juha Rinne	Hospital District of Southwest Finland, Turku, Finland
Adam Ziemann	Abbvie, Chicago, IL, United States
Jeffrey Waring	Abbvie, Chicago, IL, United States
Sahar Esmaeeli	Abbvie, Chicago, IL, United States
Nizar Smaoui	Abbvie, Chicago, IL, United States
Anne Lehtonen	Abbvie, Chicago, IL, United States
Susan Eaton	Biogen, Cambridge, MA, United States
Heiko Runz	Biogen, Cambridge, MA, United States
Sanni Lahdenperä	Biogen, Cambridge, MA, United States
Shameek Biswas	Celgene, Summit, NJ, United States
John Michon	Genentech, San Francisco, CA, United States
Geoff Kerchner	Genentech, San Francisco, CA, United States
Julie Hunkapiller	Genentech, San Francisco, CA, United States
Natalie Bowers	Genentech, San Francisco, CA, United States
Edmond Teng	Genentech, San Francisco, CA, United States
John Eicher	Merck, Kenilworth, NJ, United States
Vinay Mehta	Merck, Kenilworth, NJ, United States
Padhraig Gormley	Merck, Kenilworth, NJ, United States
Kari Linden	Pfizer, New York, NY, United States
Christopher Whelan	Pfizer, New York, NY, United States
Fanli Xu	GlaxoSmithKline, Brentford, United Kingdom
David Pulford	GlaxoSmithKline, Brentford, United Kingdom

Gastroenterology Group Martti Färkkilä

Hospital District of Helsinki and Uusimaa, Helsinki, Finland Sampsa Pikkarainen Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland

Airi Jussila

Timo Blomster Mikko Kiviniemi

Bob Georgantas Graham Heap Jeffrey Waring Nizar Smaoui Fedik Rahimov Anne Lehtonen Keith Usiskin Joseph Maranville Tim Lu Natalie Bowers Danny Oh John Michon Vinay Mehta Kirsi Kalpala Melissa Miller Xinli Hu Linda McCarthy

Rheumatology Group

Kari Eklund Antti Palomäki Pia Isomäki Laura Pirilä Oili Kaipiainen-Seppänen Johanna Huhtakangas Bob Georgantas Jeffrey Waring Fedik Rahimov

Nizar Smaoui Anne Lehtonen David Close Marla Hochfeld Natalie Bowers John Michon Dorothee Diogo Vinay Mehta Kirsi Kalpala Nan Bing Xinli Hu Jorge Esparza Gordillo Nina Mars

Pulmonology Group

Tarja Laitinen Margit Pelkonen Paula Kauppi Hannu Kankaanranta Terttu Harju Nizar Smaoui David Close Steven Greenberg Hubert Chen Natalie Bowers John Michon

Northern Ostrobothnia Hospital District, Oulu, Finland Northern Savo Hospital District, Kuopio, Finland Markku Voutilainen Hospital District of Southwest Finland, Turku, Finland Abbvie, Chicago, IL, United States Celgene, Summit, NJ, United States Celgene, Summit, NJ, United States Genentech, San Francisco, CA, United States Merck, Kenilworth, NJ, United States Pfizer, New York, NY, United States Pfizer, New York, NY, United States Pfizer, New York, NY, United States GlaxoSmithKline, Brentford, United Kingdom

Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Southwest Finland, Turku, Finland Pirkanmaa Hospital District, Tampere, Finland Hospital District of Southwest Finland, Turku, Finland Northern Savo Hospital District, Kuopio, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Abbvie, Chicago, IL, United States Abbvie, Chicago, IL, United States Abbvie, Chicago, IL, United States Apinya LertratanakulAbbvie, Chicago, IL, United States Abbvie, Chicago, IL, United States Abbvie, Chicago, IL, United States Astra Zeneca, Cambridge, United Kingdom Celgene, Summit, NJ, United States Genentech, San Francisco, CA, United States Genentech, San Francisco, CA, United States Merck, Kenilworth, NJ, United States Merck, Kenilworth, NJ, United States Pfizer, New York, NY, United States Pfizer, New York, NY, United States Pfizer, New York, NY, United States GlaxoSmithKline, Brentford, United Kingdom Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland

Pirkanmaa Hospital District, Tampere, Finland Northern Savo Hospital District, Kuopio, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Abbvie, Chicago, IL, United States Astra Zeneca, Cambridge, United Kingdom Celgene, Summit, NJ, United States Genentech, San Francisco, CA, United States Genentech, San Francisco, CA, United States Genentech, San Francisco, CA, United States Vinay MehtaMerck, Kenilworth, NJ, United StatesJo BettsGlaxoSmithKline, Brentford, United KingdomSoumitra GhoshGlaxoSmithKline, Brentford, United Kingdom

Cardiometabolic Diseases Group

Veikko Salomaa Teemu Niiranen Markus Juonala Kai Metsärinne Mika Kähönen Juhani Junttila Markku Laakso Jussi Pihlajamäki Juha Sinisalo Marja-Riitta Taskinen Tiinamaija Tuomi Jari Laukkanen Ben Challis Andrew Peterson Julie Hunkapiller Natalie Bowers John Michon Dorothee Diogo Audrey Chu Vinay Mehta Jaakko Parkkinen Melissa Miller Anthony Muslin Dawn Waterworth

Oncology Group

Heikki Joensuu Tuomo Meretoja Olli Carpen Lauri Aaltonen Annika Auranen Peeter Karihtala Saila Kauppila Päivi Auvinen Klaus Elenius **Relja Popovic** Jeffrey Waring **Bridget Riley-Gillis** Anne Lehtonen Athena Matakidou Jennifer Schutzman Julie Hunkapiller Natalie Bowers John Michon Vinay Mehta Andrey Loboda Aparna Chhibber Heli Lehtonen Stefan McDonough Marika Crohns Diptee Kulkarni

The National Institute of Health and Welfare Helsinki, Finland The National Institute of Health and Welfare Helsinki, Finland Hospital District of Southwest Finland, Turku, Finland Hospital District of Southwest Finland, Turku, Finland Pirkanmaa Hospital District, Tampere, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Northern Savo Hospital District, Kuopio, Finland Northern Savo Hospital District, Kuopio, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Central Finland Health Care District, Jyväskylä, Finland Astra Zeneca, Cambridge, United Kingdom Genentech, San Francisco, CA, United States Merck, Kenilworth, NJ, United States Merck, Kenilworth, NJ, United States Merck, Kenilworth, NJ, United States Pfizer, New York, NY, United States Pfizer, New York, NY, United States Sanofi, Paris, France GlaxoSmithKline, Brentford, United Kingdom

Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Northern Savo Hospital District, Kuopio, Finland Hospital District of Southwest Finland, Turku, Finland Abbvie, Chicago, IL, United States Astra Zeneca, Cambridge, United Kingdom Genentech, San Francisco, CA, United States Merck, Kenilworth, NJ, United States Merck, Kenilworth, NJ, United States Merck, Kenilworth, NJ, United States Pfizer, New York, NY, United States Pfizer, New York, NY, United States Sanofi, Paris, France GlaxoSmithKline, Brentford, United Kingdom

Opthalmology Group

Kai Kaarniranta Joni A Turunen Terhi Ollila Sanna Seitsonen Hannu Uusitalo Vesa Aaltonen

Marja Luodonpää Nina Hautala Heiko Runz Erich Strauss Natalie Bowers Hao Chen John Michon Anna Podgornaia Vinay Mehta Dorothee Diogo Joshua Hoffman

Dermatology Group

Kaisa Tasanen Laura Huilaja Katariina Hannula-Jouppi Teea Salmi Sirkku Peltonen Leena Koulu Ilkka Harvima Kirsi Kalpala Ying Wu David Choy John Michon Nizar Smaoui Fedik Rahimov Anne Lehtonen Dawn Waterworth

FinnGen Teams

Administration Team Anu Jalanko Risto Kajanne Ulrike Lyhs

Communication

Mari Kaunisto

Analysis Team

Justin Wade Davis Bridget Riley-Gillis Danjuma Quarless Slavé Petrovski Jimmy Liu Chia-Yen Chen Paola Bronson Robert Yang Joseph Maranville Shameek Biswas Northern Savo Hospital District, Kuopio, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Hospital District of Southwest Finland, Turku, Finland Hannele Uusitalo-Järvinen Pirkanmaa Hospital District, Tampere, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Biogen, Cambridge, MA, United States Genentech, San Francisco, CA, United States Merck, Kenilworth, NJ, United States Merck, Kenilworth, NJ, United States Merck, Kenilworth, NJ, United States GlaxoSmithKline, Brentford, United Kingdom

Northern Ostrobothnia Hospital District, Oulu, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Hospital District of Southwest Finland, Turku, Finland Hospital District of Southwest Finland, Turku, Finland Northern Savo Hospital District, Kuopio, Finland Pfizer, New York, NY, United States Pfizer, New York, NY, United States Genentech, San Francisco, CA, United States Genentech, San Francisco, CA, United States Abbvie, Chicago, IL, United States Abbvie, Chicago, IL, United States GlaxoSmithKline, Brentford, United Kingdom

Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Abbvie, Chicago, IL, United States Abbvie, Chicago, IL, United States Abbvie, Chicago, IL, United States Astra Zeneca, Cambridge, United Kingdom Biogen, Cambridge, MA, United States Biogen, Cambridge, MA, United States Biogen, Cambridge, MA, United States Celgene, Summit, NJ, United States Celgene, Summit, NJ, United States

Diana Chang Genentech, San Francisco, CA, United States Julie Hunkapiller Genentech, San Francisco, CA, United States **Tushar Bhangale** Genentech, San Francisco, CA, United States Natalie Bowers Genentech, San Francisco, CA, United States **Dorothee Diogo** Merck, Kenilworth, NJ, United States **Emily Holzinger** Merck, Kenilworth, NJ, United States Merck, Kenilworth, NJ, United States Padhraig Gormley Xulong Wang Merck, Kenilworth, NJ, United States Xing Chen Pfizer, New York, NY, United States Åsa Hedman Pfizer, New York, NY, United States GlaxoSmithKline, Brentford, United Kingdom Kirsi Auro Sanofi, Paris, France Clarence Wang Ethan Xu Sanofi, Paris, France Franck Auge Sanofi, Paris, France **Clement Chatelain** Sanofi, Paris, France Mitja Kurki Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute, Cambridge, MA, United States Samuli Ripatti Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Mark Daly Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Juha Karjalainen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute, Cambridge, MA, United States Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Aki Havulinna Anu Jalanko Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Kimmo Palin University of Helsinki, Helsinki, Finland Priit Palta Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Pietro Della Briotta Parolo Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Wei 7hou Broad Institute, Cambridge, MA, United States Susanna Lemmelä Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland University of Stanford, Stanford, CA, United States Manuel Rivas Jarmo Harju Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Aarno Palotie Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Arto Lehisto Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Andrea Ganna Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Vincent Llorens Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Antti Karlsson Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland Kati Kristiansson THL Biobank / The National Institute of Health and Welfare Helsinki, Finland Mikko Arvas Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland Kati Hyvärinen Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland Jarmo Ritari Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland **Tiina Wahlfors** Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland Miika Koskinen Hospital District of Helsinki and Uusimaa, Helsinki, Finland BB/HUS/Univ Hosp Districts Olli Carpen Hospital District of Helsinki and Uusimaa, Helsinki, Finland BB/HUS/Univ Hosp Districts Johannes Kettunen Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland Katri Pylkäs Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital Marita Kalaoja District, Oulu, Finland Minna Karjalainen Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland **Tuomo Mantere** Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Eeva Kangasniemi Tampere, Finland

Sami Heikkinen	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,
Arto Mannermaa	Kuopio, Finland Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,
	Kuopio, Finland
Eija Laakkonen	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,
Juha Kononen	Jyväskylä, Finland Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland
Sample Collection Coordinat	tion
Anu Loukola	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Sample Logistics	
Päivi Laiho	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Tuuli Sistonen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Essi Kaiharju	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Markku Laukkanen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Elina Järvensivu	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Sini Lähteenmäki	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Lotta Männikkö	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Regis Wong	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Registry Data Operations	
Kati Kristiansson	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Hannele Mattsson	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Susanna Lemmelä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Tero Hiekkalinna	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
	Manuel González Jiménez THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Genotyping	
Kati Donner	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Convencing Information	
Sequencing Informatics Priit Palta	Institute for Malagular Madicing Finland HillEF, University of Halsinki, Finland
Kalle Pärn	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Javier Nunez-Fontarnau	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
	institute for Molecular Medicine Finland, HEIFE, Oniversity of Heisinki, Finland
Data Management and IT In	frastructure
Jarmo Harju	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Elina Kilpeläinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Timo P. Sipilä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Georg Brein	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
	Oluwaseun Alexander Dada Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Ghazal Awaisa	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Anastasia Shcherban	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Tuomas Sipilä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Clinical Endpoint Developme	ent
Hannele Laivuori	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Aki Havulinna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Susanna Lemmelä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Tuomo Kiiskinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Trajectory Team	
Tarja Laitinen Harri Sürtela	Pirkanmaa Hospital District, Tampere, Finland
	LIDIVARITY AT LOMPARA LOMPARA LIDIANA

Pirkanmaa Hospital District, Tampere, Finland University of Tampere, Tampere, Finland

Harri Siirtola

Javier Gracia Tabuenca

Biobank Directors

Lila Kallio Sirpa Soini Jukka Partanen Kimmo Pitkänen Seppo Vainio Kimmo Savinainen Veli-Matti Kosma Teijo Kuopio

University of Tampere, Tampere, Finland

Auria Biobank, Turku, Finland THL Biobank, Helsinki, Finland Blood Service Biobank, Helsinki, Finland Helsinki Biobank, Helsinki, Finland Northern Finland Biobank Borealis, Oulu, Finland Tampere Biobank, Tampere, Finland Biobank of Eastern Finland, Kuopio, Finland Central Finland Biobank, Jyväskylä, Finland

Supplementary References

- 1. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).
- 2. Kuriyama, S. *et al.* The Tohoku Medical Megabank Project: Design and mission. *J. Epidemiol.* **26**, 493– 511 (2016).
- Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex traits. *Nat. Genet.* 51, 1339–1348 (2019).
- 4. Atkinson, E. G. *et al.* Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and to boost power. *Nat. Genet.* **53**, 195–204 (2021).
- 5. Benner, C. *et al.* FINEMAP: Efficient variable selection using summary data from genome-wide association studies. *Bioinformatics* **32**, 1493–1501 (2016).
- Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Ser. B Stat. Methodol.* 82, 1273– 1300 (2020).